08:48 EDT Nektar (NKTR) jumps 130% to $21.90 after atopic dermatitis study success
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar Therapeutics Announces Positive Phase 2b Trial Results
- Nektar’s rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial
- Closing Bell Movers: Futures up on Iran/Israel truce, KB Home slips on outlook
- Nektar to announce induction period in REZOLVE-AD study of Rezpegaldesleukin
- Upcoming Stock Splits This Week (June 9 to June 13) – Stay Invested